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Abstract
Background: Gene prediction is a challenging but crucial part in most genome analysis pipelines. Various methods
have evolved that predict genes ab initio on reference sequences or evidence based with the help of additional
information, such as RNA-Seq reads or EST libraries. However, none of these strategies is bias-free and one method
alone does not necessarily provide a complete set of accurate predictions.
Results: We present IPred (Integrative gene Prediction), a method to integrate ab initio and evidence based gene
identifications to complement the advantages of different prediction strategies. IPred builds on the output of gene
finders and generates a new combined set of gene identifications, representing the integrated evidence of the single
method predictions.
Conclusion: We evaluate IPred in simulations and real data experiments on Escherichia Coli and human data. We
show that IPred improves the prediction accuracy in comparison to single method predictions and to existing
methods for prediction combination.
Keywords: Gene prediction, Gene finder combination, Genome annotation, RNA-Seq integration
Background
Predicting the genes encoded in the genome of an organ-
ism is a crucial part of most pipelines for genomic anal-
ysis. Driven by the ongoing advances of high-throughput
next-generation sequencing techniques, more and more
genome sequences are available that need to be annotated
to understand the basis and function of processes in a cell.
To allow accurate predictions, several methods for gene
identification have evolved, which can be categorized as
ab initio and evidence based (including comparative) gene
finders. ab initio approaches (for instance [1,2]) predict
genes exclusively depending on the target sequence and
perform identifications based on training data and strate-
gies such as Hidden Markov models [3].
In contrast, evidence based methods compare the
sequence of interest to available reference annotations or
include external evidence in their prediction, for example
EST libraries or RNA-Seq information [4-6].
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ab initio methods are very sensitive, but their accuracy
strongly depends on the quality of the training data set
[3]. Further, they have the disadvantage (i) of providing no
information on whether the genes are indeed expressed
under a certain condition or not, and (ii) of missing or
incorrectly predicting genes that differ from the consid-
ered standard codon scheme [7]. These criteria are met
by evidence based approaches that report genes based
on observed evidence and are therefore more robust to
non-standard coding schemes. However, these methods
are prone to noise in the external information and to
incomplete or contradicting evidence [8].
Hybrid approaches, such as AUGUSTUS [9] and
JIGSAW [10], combine ab initio predictions with other
evidence. This allows a more accurate verification of pre-
dicted genes, although also hybrid approaches are limited
for instance by incomplete evidence or insufficient train-
ing data.
Combining the output of different gene prediction
strategies allows complementing the strengths of sin-
gle method predictions to obtain the sensitivity of ab
initio approaches, while incorporating other evidence
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to complete and verify identifications, as for example
shown in [11] and [12]. Up to now, to the best of our
knowledge, approaches combining predictions treat all
identifications independently of their prediction strat-
egy and predominantly introduce weighting schemes to
score different predictions. Amongst others, these meth-
ods include [7,13-17]. Hence, the full complementary
potential of the combination of different prediction strate-
gies is not fully tapped. Further, current methods often
focus on the integration of a specific set of gene finders
[18].
Therefore, in this article we present IPred (Integra-
tive gene Prediction), an automated pipeline to process
the output of various gene finders (not focused on cer-
tain methods) and merge ab initio and evidence based
predictions to obtain a new combined set of gene iden-
tifications, representing the integrated information of the
single method predictions. In particular, IPred is inde-
pendent of the evidence used to assist gene predictions.
It incorporates methods from the full plethora of evi-
dence sources, for instance from EST libraries, protein
alignments, sequence comparison, or from increasingly
popular RNA-Seq runs. IPred was designed with a focus
on combining different prediction strategies to comple-
ment their advantages and counterbalance weaknesses
of one prediction class with information from another.
True positive identifications, for instance highly con-
served genes, are likely to be present throughout different
evidence information, whereas false positive identifica-
tions are not expected to be simultaneously present
in the majority of prediction results and can thus be
filtered out.
IPred is a flexible and robust method that in contrast
to other methods works independently from weighting
schemes and does not require any a priori knowledge.
In case a reference annotation is available, all predic-
tions can be automatically evaluated using the framework
provided by Cuffcompare [19].
IPred provides its own GUI for easy usability, but can
also be applied from the command line. We demonstrate
the benefit of our method in two simulations and in
two real data experiments based on Escherichia Coli and
human data.
Implementation
IPred accepts prediction output files in the commonly
used GTF annotation format and provides converter
scripts for a range of further file formats, for example the
AUGUSTUSGFF format or the Glimmer3 Predict format.
The interpretation of GTF format styles can differ among
methods. We decided to work based on the GTF format
used by the Cufflinks/Cuffcompare suite [19] because we
use Cuffcompare in the IPred pipeline (see description
below).
Hence, in the following the name gene describes a locus
on a genome that is expressed to an amino acid sequence.
In eukaryotes, a gene can be expressed in more than one
transcript sequence, also referred to as alternative iso-
forms. Further, the transcribed part of a gene including
coding sequence (CDS) and potentially also untranslated
sequence (UTR) is called exon.
When providing the output of gene finders, the user
needs to categorize the different outputs into either ab
initio or evidence based (including comparative method
based) predictions since IPred was in particular designed
for combining complementary strategies.
Also hybrid prediction methods and the result of anno-
tation pipelines can be incorporated into IPred. For
instance, if a hybrid method is ab initio in its nature, it
should be specified as ab initio. When evidence has been
integrated in the annotation pipeline, the result can be
specified as evidence based.
Note that it is not recommended to combine ab initio
with ab initio methods since the underlying informa-
tion, i.e. training sets or employed statistical model, might
be very similar and thus could bias the combination of
predictions.
However, if an integration of two ab initio predictions is
desired, one method can be classified as evidence based.
Here, it is necessary to keep in mind that potential novel
genes that are predicted by the ab initio method (that is
classified as evidence based) are genes that are not verified
by external evidence.
Based on the categorization of each method, IPred first
processes the loci of the predicted genes separately and
then combines the loci of ab initio and evidence based
methods. IPred proceeds through the predicted ab ini-
tio loci (also called “leading" loci) and tests if an evidence
based prediction supports this identification. During this
process the supported ab initio predictions are catego-
rized into genes that perfectly overlap with at least one
evidence based prediction and minor supported predic-
tions that have only partial overlap. Note that IPred per
default accepts an overlap as a supporting overlap only
if it is greater than a threshold of 80% of the length of
the original ab initio prediction (calculated as the sum of
the number of nucleotides of its exons). The reason for the
acceptance of only partially overlapped genes is that evi-
dence based methods might only partially predict a gene,
e.g. due to low coverage in RNA-Seq experiments. Hence,
requiring a perfect overlap could result in missed predic-
tions. The threshold for overlap acceptance can be set by
the user and is also adjustable to only accept 100% over-
laps (i.e. perfect overlaps). In the Additional file 1 we show
that IPred is robust to different threshold settings and that
it is not biased by small overlap thresholds.
If at least two evidence based prediction outputs are
available, the former described merging process can
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be extended by also reporting genes that are not pre-
dicted ab initio, but have support from different evi-
dence based gene finders. This way, potential novel genes
can be identified with greater confidence and also with
respect to different approaches and sources for including
external information (e.g. RNA-Seq evidence versus EST
evidence).
IPred distinguishes between combinations of prokary-
otic predictions and eukaryotic predictions since the
structure of gene loci can differ substantially depending
on the organism type. In contrast to prokaryotes, eukary-
otes show splicing events and also alternative splicing
resulting in alternative transcript isoforms. This needs to
be respected when merging eukaryotic gene predictions.
Hence, for each gene locus all corresponding transcripts
are processed separately. It is not only important that an
exon of a predicted transcript is supported by other meth-
ods, but also that the exon chain - all neighboring exons
- is similar for compared transcripts (because differences
indicate an alternative isoform).
Hence, in case of eukaryotes IPred only regards sup-
port for an exon of a transcript if the overlapping exon
is part of a similar exon chain from a second prediction
method. A transcript is classified as “perfect" only if all
exons are matched perfectly by a different method. In case
all exons of a transcript are supported, but with minor
differences (specified by the overlap threshold), the tran-
script is still classified as “supported" but receives a lower
score to indicate less agreement.
If only a part of the exons of a transcript is matched,
IPred tests if the overlapping transcripts predicted by
other methods have stronger support (i.e. they differ
from the currently leading transcript, but agree with each
other). If this is the case, the leading transcript is regarded
as incorrect and instead the overlapping transcripts with
stronger support are taken into account.
If the possibly overlapping transcripts also disagree, the
leading transcript is accepted only if the chosen overlap
threshold is met by the number of matched exons (for the
leading transcript as well as the chosen overlapping other
prediction). Since the original overlap threshold is defined
as a percentage of nucleotides that need to be covered, the
definition of the transcript overlap threshold t is slightly
adapted: The number of overlapped exons k must exceed
t percent of the total number of exons n that are part of
the current transcript: k ≥ t · n.
IPred outputs a new prediction file in GTF format that
includes all genes supported by both prediction strate-
gies, categorized by the reliability of each prediction. In
addition, a tracking file reports the original genes that
generated each merged IPred prediction. Further, addi-
tional files reporting genes that were only supported
by one strategy are provided, e.g. to allow the analy-
sis of potential novel or not expressed genes. In case a
reference annotation is available, all predictions can be
automatically evaluated using the framework provided by
Cuffcompare [19] to allow an easy comparison of different
combinations of gene finders.
It is important to keep inmind that IPred is not intended
as a new gene finder but rather as an easy-to-use post pro-
cessing analysis to verify predictions and to filter out false
positives. Therefore, it strongly depends on the quality
and performance of the input gene finders, but is inde-
pendent of the underlying data sets or the nature of the
information used for evidence based prediction. Hence,
IPred is in principle capable of detecting rare or hard-to-
predict events, for instance also ncRNA genes or genes
following a non-standard coding scheme, as long as at
least some of the input gene finders predict those events.
Currently, IPred returns predictions following the GTF
format as interpreted in the Cufflinks suite, e.g. it does
not specify UTR features. The reason is that currently
the output formats of gene finders strongly differ between
methods, and often no UTRs or CDS are reported. Hence,
to ensure a broad applicability we decided to be indepen-
dent of these features and concentrated on gene loci and
their corresponding transcripts and used the exon feature
to specify coding regions.
Details on the merging process and system require-
ments are shown in the Additional file 1.
Experimental setup
We evaluated IPred in four experiments on E.Coli (NCBI-
Accession: NC_000913.2) and human data (GRCh37). To
compare the methods on well-defined known ground
truth data, we not only used real data sets but also sim-
ulations in our evaluation. In the first E.Coli experiment
we combined predictions of the widely used ab initio gene
finders GeneMark [20] and GLIMMER3 [2] and the evi-
dence based gene finders GIIRA [6] and Cufflinks [21].
We simulated RNA-Seq reads based on the NCBI refer-
ence annotation of E.Coli as evidence information. In the
second experiment we used real E.Coli RNA-Seq reads
(SRA-Accession: SRR546811) as evidence.
The eukaryotic experiments were also analyzed with
Cufflinks and GIIRA, as well as with AUGUSTUS [9], a
hybrid gene finder that is capable of integrating evidence
into its ab initio predictions. In the eukaryotic simula-
tion we again used simulated RNA-Seq reads as additional
evidence. Further, real RNA-Seq reads (SRA-Accession:
SRR1654792) served as evidence for the human real data
experiment.
All gene prediction methods were applied in their stan-
dard settings, using pre-trained models if available. The
incorporation of hints to AUGUSTUS followed the stan-
dard pipeline recommended on the AUGUSTUS web
page. Note that the use of pre-trainedmodels might intro-
duce a bias favoring the accuracy of ab initio based gene
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finders, due to possible similarities between training data
and the data used in this study. However, the comparison
of prediction combination methods is unaffected since all
combinations are based on the same single method pre-
dictions. Full details on the method configurations can be
found in the Additional file 1.
The simulation setup uses the read simulator Mason
[22] applied to the NCBI reference annotation for each
organism of interest. In this annotation the coding
sequence of each known isoform appears as a consecutive
sequence. Hence, the simulated reads show similar char-
acteristics as real RNA-Seq reads since they cover alterna-
tive isoforms, span introns (if existing in the data set) and
show a coverage profile typical for gene expression. Note
that only 70% of the annotated genes were used for evi-
dence generation, simulating the fact that not all genes are
expressed at the same time. The genes that received RNA-
Seq support were chosen as the ground truth annotation
for the simulation experiments. To obtain a ground truth
in the real data experiments, we performed an alignment
of the RNA-Seq reads against the reference annotation
and counted the number of reads mapping to each anno-
tated gene. Then we regarded all genes as present that
received an overall coverage of at least one.
The simulated and real reads were aligned to the refer-
ence genome using TopHat2 [23], and the resulting align-
ment served as evidence for hybrid and evidence based
gene prediction. The ab initio gene finders were applied
directly on the reference genomes.
IPred was used to analyze and combine the resulting
gene predictions. We ran Cuffcompare [19] to evaluate all
single method predictions and combinations against the
ground truth reference annotations. In addition, we com-
pared IPred to gene prediction combinations obtained
by Cuffmerge [19] and EVidenceModeler [13], a current
state-of-the-art prediction combiner that is an extension
of the Combiner idea [15] and was shown to have superior
performance to other existing combiners such as GLEAN
[14] and JIGSAW [10]. The simulation framework and
evaluation is detailed in the Additional file 1.
Results and discussion
E.Coli simulation
Figure 1 shows sensitivity, specificity and F-measure (rep-
resenting the overall prediction accuracy) for the single
method gene predictions and different combinations gen-
erated by IPred. Overall, we see a large improvement
in specificity (e.g. from 63.8% to 98.1% for GeneMark
only and GeneMark combined with Cufflinks), while also
improving or yielding comparable sensitivity.
Hence, the overall prediction accuracy is significantly
improved for combined predictions, as reflected in the
considerable higher F-measures. Also the number of
missed and novel (not annotated in ground truth, hence
false positive) genes is reduced when combining meth-
ods. GeneMark and GIIRA originally resulted in a high
number of non-annotated predictions. However, when
integrating both methods, the merged result shows a sub-
stantially reduced number. This indicates that erroneous
predictions are filtered out during the merging process
because an erroneous prediction by one of the methods is
almost always not present in the other method.
Further, we see different effects on prediction accuracy
depending on the evidence based method combined with
GeneMark predictions. For example, Cufflinks appears to
yield a set of predictions that is more complementary to
GeneMark than GIIRA predictions because the combina-
tion of GeneMark and Cufflinks leads to a higher sensi-
tivity and fewer missed exons than GeneMark combined
with GIIRA.
The significant accuracy improvement of combina-
tions with Cufflinks in comparison to predictions from
Cufflinks alone is due to the fact that Cufflinks does not
predict structural genes but only the expressed transcript.
Hence, its original sensitivity and specificity are compa-
rably low, but are substantially increased when combined
with other methods predicting structural genes.
Although the combination of two gene finders already
results in improved accuracy, the combination of all three
methods yields the most accurate results. Further, when
also genes missed by GeneMark but supported by both of
the evidence based methods are taken into account, we
note an additional increase in sensitivity while showing
comparable specificity.
Independently of the chosen combination IPred out-
performs EVidenceModeler and Cuffmerge with signif-
icantly increased sensitivity and specificity. Cuffmerge
and in some cases also EVidenceModeler even results in
smaller sensitivity and specificity compared to the single
method predictions. We assume that the low accuracy of
Cuffmerge is due to the fact that it does not include any
weighting of different prediction methods, as opposed to
EVidenceModeler and the strategy combination of IPred.
A more detailed analysis of the E.Coli evaluation is shown
in the Additional file 1.
Human simulation
IPred was also tested on a simulation of a eukaryotic
dataset based on chromosomes 1, 2 and 3 of the human
genome. Figure 2 shows the exon and transcript level com-
parison of the single method prediction accuracy with
IPred, EVidenceModeler and Cuffmerge combinations.
Details are shown in the Additional file 1.
Overall, we see that the performance on exon and tran-
script level significantly differs between methods. On the
exon level, the sensitivity of IPred combinations strongly
depends on the integration of novel predictions. If only
predictions present in both AUGUSTUS and one or two
Zickmann and Renard BMCGenomics  (2015) 16:134 Page 5 of 8
Figure 1 E.Coli simulation. Overview of Cuffcompare metrics for the predictions of single methods, EVidenceModeler and IPred combinations for
the E.Coli simulation. Note that “IPred_all+novel” reports overall supported genes as well as genes missed by GeneMark but supported by both of
the evidence based methods.
of the evidence based methods are taken into account,
the sensitivity is significantly reduced compared to all
other combinations. At the same time the specificity is on
a comparable or slightly higher level compared to other
IPred combinations, and significantly higher than the EVi-
denceModeler and Cuffmerge prediction. This results in
an accuracy comparable to EVidenceModeler but sub-
stantially decreased in comparison to other IPred com-
binations and also decreased in comparison to the single
method predictions.
If predictions are included that do not overlap with
AUGUSTUS identifications (either not sufficiently with
Figure 2 Human simulation. Overview of Cuffcompare metrics for the predictions of single methods and method combinations for the simulated
human data set. On the left-hand side the exon level evaluation is shown, on the right-hand side the comparison on the transcript level. Note that
“IPred_all+nov" reports overall supported genes as well as genes missed by AUGUSTUS but supported by both of the evidence based methods.
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respect to the overlap threshold or not at all), the sen-
sitivity significantly increases, together with only slight
decrease in specificity. Hence, these IPred combinations
clearly outperform the result of EVidenceModeler. Also
the Cuffmerge combinations are outperformed since the
high sensitivity of Cuffmerge is accompanied with signifi-
cantly lower specificity.
The reason for the performance difference between
combinations including and excluding “novel” predic-
tions is that AUGUSTUS often reports a transcript with
an incorrect first or last exon (i.e. it reports an addi-
tional exon, data not shown). This is also reflected in the
high number of novel exons predicted by AUGUSTUS
and in its low specificity. Though a detailed analysis
of this phenomenon is beyond the scope of this work,
a likely explanation is that AUGUSTUS is in princi-
ple an ab initio gene finder and only integrates hints
from other evidence. The additional exons might be
an artifact due to the ab initio prediction (that also
predicts genes that are not expressed in our simula-
tion). Hence, in combinations with Cufflinks and GIIRA
the exon chains of the compared methods disagree
and none of the predictions appears to be sufficiently
supported.
Although including novel genes significantly increases
the sensitivity, IPred is still affected by the discrepan-
cies between AUGUSTUS and evidence based predictions
because it shows a sensitivity only comparable to Cufflinks
and GIIRA and therefore yields comparable results in the
overall accuracy.
All in all, on the exon level IPred (including genes
not fully supported by AUGUSTUS) yields more accu-
rate results than EVidenceModeler and Cuffmerge and
comparable results to the best single methods.
On the transcript level Cufflinks as the best performing
method on the exon level yields almost no perfectly pre-
dicted transcripts. This is due to the fact that Cufflinks is
very accurate at predicting intermediate exons but does
not predict start and stop codons and therefore beginning
and the end of a transcript almost never match the refer-
ence annotation. Here, IPred proves very useful because
it can complement the overall exon accuracy of Cufflinks
with the start and stop prediction accuracy of other meth-
ods, which is reflected in the strong increase in sensitivity
and specificity compared to Cufflinks alone.
Hence, IPred again yields more accurate predictions
than EVidenceModeler and Cuffmerge. Further, it also
increases the accuracy of the single method predictions.
Detailed values of the Cuffcompare evaluation are shown
in the Additional file 1.
In addition, we compared the performance of the three
gene prediction combination methods in regard to mem-
ory consumption and speed. Table 1 shows the peakmem-
ory and overall time necessary to analyze and combine
Table 1 Overall running time (in seconds) and peak
memory (in megabytes) for the compared gene prediction
combinationmethods to analyze the simulated human
data set
Performance evaluation
Combinationmethod Overall time (s) Peak memory (MB)
EVidenceModeler 23 037 3 100
Cuffmerge 132 624
IPred 59 215
the single method predictions. IPred has the lowest mem-
ory and running time requirements of the three compared
gene prediction combination methods.
E.Coli real data set
For further evaluation we also applied IPred to E.Coli pre-
dictions based on real RNA-Seq evidence. Figure 3 shows
the results of the Cuffcompare evaluation against the
subset of likely expressed reference annotations. A more
detailed analysis can be found in the Additional file 1.
Overall, IPred combinations show a pronounced
increase in specificity and result in significantly improved
prediction accuracy compared to all othermethods. Glim-
mer3 shows the highest sensitivity of all methods. Since
none of the approaches that include RNA-Seq evidence
show a comparable sensitivity, this is likely due to the
choice of the ground truth annotation set that might
still contain genes that are not expressed but are rather
mapping artifacts. Here, including other evidence, such
as protein alignments, might even further increase the
accuracy of combined predictions. Cufflinks and also
Cuffmerge show very low accuracy, which indicates that
they are more suitable for application on eukaryotes than
on prokaryotes.
Human real data set
The results of the evaluation on a complete human data
set with real RNA-Seq reads are shown in Figure 4 and are
detailed in the Additional file 1.
On exon as well as transcript level AUGUSTUS shows
the highest prediction sensitivity, while the IPred com-
binations (without including potential novel genes) show
the highest specificity. This further demonstrates that
IPred successfully excludes false positive predictions.
However, on the exon level the overall accuracy of
AUGUSTUSpredictions (79.9%) is slightly higher than the
accuracy of combinations by IPred based on Cufflinks or
Cufflinks and GIIRA (79.6% and 77.2%).
On the transcript level the difference in sensitivity is not
as pronounced as on the exon level. Hence, here the over-
all accuracy of IPred predictions (without potential novel
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Figure 3 E.Coli real data. Overview of Cuffcompare metrics for the predictions of the single methods, EVidenceModeler, Cuffmerge, and IPred
combinations for the real E.Coli data set.
genes) is slightly higher than for AUGUSTUS, due to the
improved specificity of IPred.
On this data set including potentially novel genes also
resulted in higher sensitivity (on the exon level more
pronounced than on the transcript level); however, at
the cost of reduced specificity and overall reduced accu-
racy. This indicates that although Cufflinks and GIIRA
agree on certain expressed regions, these predictions still
require further analysis to ensure that they are not map-
ping artifacts. However, these regions might also hint
to novel genes, but additional evidence, for instance
from ESTs or protein libraries would be necessary for
further verification, which is beyond the scope of this
manuscript.
In comparison with Cuffmerge and EVidenceModeler,
IPred shows improved prediction accuracy, in particular
on the transcript level. On the exon level, combinations
by EVidenceModeler are comparable to IPred. Cuffmerge
shows the highest exon level sensitivity of all combination
methods, but at the cost of the lowest specificity.
Figure 4 Human real data. Overview of Cuffcompare metrics for the predictions of single methods and method combinations for the complete
human real data set. On the left-hand side the exon level evaluation is shown, on the right-hand side the comparison on the transcript level. Note
that “IPred_all+nov" reports overall supported genes as well as genes missed by AUGUSTUS but supported by both of the evidence based methods.
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Conclusion
Gene prediction is an important task in genome analysis
pipelines. Existing approaches aim at accurately identify-
ing genes based on varying strategies, categorized as ab
initio and evidence based. Since both types have their
own strengths and weaknesses, combining ab initio and
evidence based methods can complement advantages to
improve the overall prediction accuracy. We developed
IPred, an automated pipeline to integrate the results of
gene prediction methods based on different strategies to
enhance the accuracy of the combined gene identifica-
tions. The benefit is shown in simulations and on real data:
IPred shows favorable sensitivity and specificity compared
to single method predictions and to existing combiners.
Thus, we believe that IPred is a valuable addition to
the set of existing methods for prediction combination. It




Project home page: https://sourceforge.net/projects/
ipred/.
Operating systems: Platform independent.
Programming language: Python (main software) and
Java (GUI).
Other requirements: Java 7 is required for using the GUI.
Further, for using IPred from source, Python 2.7 or higher
and the packages Matplotlib and Numpy are required.
License: GNU Lesser General Public License, version 3.0.
Any restrictions to use by non-academics:No.
Additional file
Additional file 1: Supplementary material to IPred. PDF document
containing supplementary information on methods, system requirements,
experimental setup, and results.
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